Drug Channel Updates
Timely updates on drug shortages, launches, recalls, and more.
Top shortages
Amoxicillin 400mg/5ml 75ml Manufacturer on back order. Increased demand causing this issue.
Cefdinir 250mg/5ml 60ml Manufacturer on back order. Increased demand causing this issue.
Diclofenac Sod 1% Top 100gm Product being allocated by manufacturer.
Diltiazem 240mg Er 30’s Manufacturer on back order.
Diltiazem 180mg Er 30’sProduct in stock or in transit to all distribution centers.
Gentamicin 0.3% 5ml Manufacturer on back order.
Levlbutrl Tart Hfa 45mcg 15gm Manufacturer on back order.
Naltrexone HcL 50mg 30’s Product being allocated by manufacturer.
Progesterone 100mg 100’s Product being allocated by manufacturer.
Drug Launches
The latest insights on the drug market.
Recent Launches
Myrbetriq (Mirabegron) is a $2.7 billion market and launched April 23. Zydus is our source vendor.
Upcoming Launches
Sandostatin LAR (octreotide acetate) is a $1.5 billion market and is expected to launch in early May. Teva is our source vendor.
Victoza (liraglutide recombinant) is a $3.7 billion market and is expected to launch mid-to-late June. Teva is our source vendor.
Oxtellar XR (oxcarbazepine) is a $210 million market and is scheduled to launch early May. However, a new patent has been presented, which may delay this launch.
Oxtellar XR (oxcarbazepine) is a $210 million market and is scheduled to launch sometime in early-to-mid September. No source vendor has been selected.
Sprycel (dasatinib) is a $2.3 billion market. It’s scheduled to launch sometime in mid-to-late September. No source vendor has been selected.
Rayos (prednisone) is a $120 million market. Its launch has been delayed several times.
Day 181
Onexton (clindamycin phos/benzoyl perox gel w/pump) is a $117 million market and will be available in May or June. Taro is the source vendor.
Pradaxa (dabigatrain etexilate mesylate) is a $112 million market and Apotex will be the source vendor.
Condylox (podofilox gel) is an $11 million market. Padagis is the current source vendor and others are expected in June.
Prolensa (bromfenac sodium) is a $186 million market. Lupin will be the source vendor.
Indocin OS (indomethacin oral susp) is a $5 million market. ANI will be the source vendor.
BromSite (bromfenac sodium drops) is a $30 million market. Lupin will be our source vendor.
Rectiv (nitroglycerin oint) is a $23 million market. Cosette will be our source vendor.
Recalls
The most recent recall information with return forms.
Dr. Reddy’s
Sapropterin Dihydrocholoride Powder for Oral Solution 100 mg
Reason for recall: Decreased potency
Company name: Dr. Reddy’s Laboratories, Inc.
Schwinnng
Herbal dietary supplement
Reason for recall: Product tainted with Nortadalafil
Company name: STOP CLOPEZ CORP
Aruba Aloe
Hand Sanitizer Gel and Alcoholada Gel
Reason for recall: Product contains methanol
Company name: Aruba Aloe Balm N.V.
Fendall 2000
Non-sterile eyewash cartridge
Reason for recall: Non-compliance with current good manufacturing practice (cGMP) requirements
Company name: Honeywell Safety Products USA
ForeverMen
Natural energy boost
Reason for recall: Product tainted with sildenafil and tadalafil
Company name: FAonline Inc
AVpak
Atovaquone Oral Suspension, USP 750mg/5mL
Reason for return: Potential bacillus cereus contamination
Company name: AvKARE, LLC